Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04372277

Taltz in Combination With Enstilar for Psoriasis

Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
25 (estimated)
Sponsor
Psoriasis Treatment Center of Central New Jersey · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Enstilar in combination with Taltz for plaque psoriasis.

Detailed description

A single center study of 25 subjects to assess the addition of Enstilar Foam in patients receiving Taltz for ≥ 24 weeks with BSA between 3% and 8%.

Conditions

Interventions

TypeNameDescription
DRUGEnstilartopical Enstilar foam

Timeline

Start date
2020-04-28
Primary completion
2021-03-01
Completion
2021-03-30
First posted
2020-05-04
Last updated
2020-05-04

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04372277. Inclusion in this directory is not an endorsement.

Taltz in Combination With Enstilar for Psoriasis (NCT04372277) · Clinical Trials Directory